Skip to main content
LLY
NYSE Life Sciences

Eli Lilly Completes $9.0 Billion Debt Offering, Funds Centessa Acquisition

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$1,016.97
Mkt Cap
$959.512B
52W Low
$623.78
52W High
$1,133.95
52W Position info
63% above low
Off High info
10% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

LLY sits 63% above its 52-week low of $623.78.

Summary

Eli Lilly completed a $9.0 billion debt offering, raising approximately $8.94 billion in net proceeds, with a significant portion explicitly tied to financing the previously announced Centessa acquisition.


Key Events · Financing and Capital Events · LLY

  • Completed $9.0 Billion Debt Offering

    Eli Lilly completed an offering of various Floating Rate Notes and Fixed Rate Notes totaling $9.0 billion in aggregate principal amount.

  • Raised $8.94 Billion in Net Proceeds

    The company received approximately $8.94 billion in net proceeds from the debt offering, after deducting underwriting discounts.

  • Financing Linked to Centessa Acquisition

    A significant portion of the notes ($6.25 billion) are subject to a special mandatory redemption if the Centessa Acquisition is not consummated by March 31, 2027, explicitly linking the financing to the previously announced $6.3 billion acquisition.

  • Diverse Note Maturities and Rates

    The offering includes both floating and fixed-rate notes with maturities ranging from 2028 to 2066, diversifying the company's debt profile.


Analysis · LLY · Life Sciences

Eli Lilly has successfully completed a substantial debt offering, raising approximately $8.94 billion in net proceeds. This capital raise is significant for funding the company's strategic growth initiatives. A key detail is the special mandatory redemption clause for $6.25 billion of the notes, explicitly linking this financing to the previously announced Centessa acquisition. This demonstrates the company's commitment to its M&A strategy and provides the necessary capital to execute it, following a period of strong operational performance and product development.

At the time of this filing, LLY was trading at $1,016.97 on NYSE in the Life Sciences sector, with a market capitalization of approximately $959.5B. The 52-week trading range was $623.78 to $1,133.95. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LLY - Latest Insights

LLY
Aug 05, 2026, 2:40 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1,158.26
Real-time Price: $1,190.01 info
Change: +$31.75 (+3%) info
Market Cap: $1.122T info
LLY
Aug 05, 2026, 12:06 PM EDT
Source: Benzinga
Importance Score:
9
Price at Filing: $1,156.57
Real-time Price: $1,190.01 info
Change: +$33.44 (+3%) info
Market Cap: $1.122T info
LLY
Aug 05, 2026, 7:23 AM EDT
Source: Binance News
Importance Score:
9
Price at Filing: $1,170.05
Real-time Price: $1,190.01 info
Change: +$19.96 (+2%) info
Market Cap: $1.122T info
LLY
Aug 05, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1,170.05
Real-time Price: $1,190.01 info
Change: +$19.96 (+2%) info
Market Cap: $1.122T info
LLY
Aug 05, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $1,141.30
Real-time Price: $1,190.01 info
Change: +$48.71 (+4%) info
Market Cap: $1.122T info